CompanyJuly 27, 2026329 Views
Huayuu Biopharma Completes Series B Funding
The company successfully completed Series B funding of 500 million RMB.
Hangzhou Huayuu Biopharma Co., Ltd. (HUAYUU) recently announced the completion of Series B funding of 500 million RMB, led by several renowned investment institutions. The funds will be used to accelerate clinical advancement of core pipelines and industrial base construction.

